Pharmacokinetics of landiolol hydrochloride, a new ultra‐short‐acting β‐blocker, in patients with cardiac arrhythmias

  title={Pharmacokinetics of landiolol hydrochloride, a new ultra‐short‐acting $\beta$‐blocker, in patients with cardiac arrhythmias},
  author={Hirotsugu Atarashi and Akinori Kuruma and Masaaki Yashima and Hirokazu Saitoh and Takeshi Ino and Yasumi Endoh and Hirokazu Hayakawa},
  journal={Clinical Pharmacology \& Therapeutics},
To elucidate pharmacokinetics and pharmacodynamics of landiolol hydrochloride, newer developed ultra‐short‐acting β‐blocker, in patients with various cardiac tachyarrhythmias. 

Effect of landiolol hydrochloride, an ultra‐short‐acting beta 1‐selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection

The objective of this study was to investigate the efficacy of landiolol hydrochloride, an ultra‐short‐acting β1‐blocker, in patients with post‐operative supraventricular tachycardia after pulmonary resection.

Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting

New insight is provided on landiolol, an ultra-short acting injectable betablocker, recently approved in Europe, with regard to its pharmacokinetic and pharmacodynamic profile, along with its first experience in Caucasian healthy volunteers and patients with atrial fibrillation.

Dose-Dependent Effect of Landiolol, a New Ultra-Short-Acting β1-Blocker, on Supraventricular Tachyarrhythmias in Postoperative Patients

The overall results demonstrate that landiolol is effective and useful for the treatment of postoperative SVT, and one patient with sick sinus syndrome developed an approximately 5-s cardiac arrest.

Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis.

Landiolol safely reduced heart rate and, in part, converted to sinus rhythm in septic patients with supraventricular tachyarrhythmias, and was observed more frequently in the landiolol group than in the control group.

Influence of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Landiolol Hydrochloride, an Ultra-Short-Acting β1-Blocker

Although the authors did not observe any drug-related adverse events in these patients, hypotension or bradycardia should be considered, necessitating continuous monitoring of both heart rate and BP in patients with hepatic impairment who receive landiolol hydrochloride.

Intravenous infusion of ultra-short-acting β-blocker for postoperative atrial fibrillation is the one of choice.

  • M. Akaishi
  • Medicine
    Circulation journal : official journal of the Japanese Circulation Society
  • 2012
If it appears, intravenous verapamil or diltiazem, or oral β-blocker, is often administered empirically in the clinical setting in Japan, and onsite management is allowed because most episodes of AF spontaneously convert to sinus rhythm.

Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients.

  • G. StixM. Wolzt G. Krumpl
  • Medicine
    Circulation journal : official journal of the Japanese Circulation Society
  • 2019
Investigation of the suitability of landiolol, an ultra-short-acting β1-specific β-blocker, for the treatment of atrial fibrillation/atrial flutter in Caucasian patients found it suitable for the acute treatment of tachycardic AF/AFL.

Effects of landiolol, an ultra-short-acting beta1-selective blocker, on electrical storm refractory to class III antiarrhythmic drugs.

  • Y. MiwaT. Ikeda H. Yoshino
  • Medicine
    Circulation journal : official journal of the Japanese Circulation Society
  • 2010
Landiolol is useful as a life-saving drug for class III antiarrhythmic drug-resistant ES, and the main mechanism of ES refractory to class IIIAntiarrhythmmic drugs could be abnormal automaticity but not reentry.



Development of a Highly Cardioselective Ultra Short-Acting β-Blocker, ONO-1101

A novel, highly cardioselective ultra short-acting β-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This

Kinetics of esmolol, an ultra‐short‐acting beta blocker, and of its major metabolite

Esmolol was followed by a significant reduction of isoproterenol‐induced increase in heart rate and systolic blood pressure at doses of 50, 150, and 400 μg/kg/min, indicating that nonhepatic routes play a predominant role in its clearance.

Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia.

Intention-to-treat analysis showed no difference in the incidence of arrhythmia recurrence, sudden death, or total mortality between the two groups of metoprolol and sotalol.

Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.

In the majority of patients (80%), therapeutic response was lost within 30 minutes following discontinuation of esmolol infusion, a finding indicative of rapid reversal of beta-adrenoceptor blockade.

A double-blind trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias.

Despite a lack of effect on less serious ventricular tachyarrhythmias, metoprolol had a prophylactic effect against ventricular fibrillation in acute myocardial infarction.